AR079340A1 - Anticuerpos anti-c4.4a y usos de los mismos - Google Patents

Anticuerpos anti-c4.4a y usos de los mismos

Info

Publication number
AR079340A1
AR079340A1 ARP100104549A ARP100104549A AR079340A1 AR 079340 A1 AR079340 A1 AR 079340A1 AR P100104549 A ARP100104549 A AR P100104549A AR P100104549 A ARP100104549 A AR P100104549A AR 079340 A1 AR079340 A1 AR 079340A1
Authority
AR
Argentina
Prior art keywords
antibodies
antigen binding
cancer
binding regions
disorders
Prior art date
Application number
ARP100104549A
Other languages
English (en)
Spanish (es)
Inventor
Beatrix Stelte-Ludwig
Juergen Franz
Yong-Jiang Cao
Axel Harrenga
Simone Greven
Ricarda Finnern
Frank Dittmer
Anke Mayer-Bartschmid
Lars Linden
Gabriele Leder
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR079340A1 publication Critical patent/AR079340A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP100104549A 2009-12-09 2010-12-09 Anticuerpos anti-c4.4a y usos de los mismos AR079340A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09178474 2009-12-09
EP10170797 2010-07-26

Publications (1)

Publication Number Publication Date
AR079340A1 true AR079340A1 (es) 2012-01-18

Family

ID=43629588

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104549A AR079340A1 (es) 2009-12-09 2010-12-09 Anticuerpos anti-c4.4a y usos de los mismos

Country Status (27)

Country Link
US (2) US20120321619A1 (OSRAM)
EP (2) EP2510012B1 (OSRAM)
JP (3) JP5989544B2 (OSRAM)
KR (1) KR101931820B1 (OSRAM)
CN (1) CN102812047B (OSRAM)
AR (1) AR079340A1 (OSRAM)
AU (1) AU2010329904B2 (OSRAM)
BR (1) BR112012013915A8 (OSRAM)
CA (1) CA2783338A1 (OSRAM)
CY (1) CY1119051T1 (OSRAM)
DK (1) DK2510012T3 (OSRAM)
ES (1) ES2632748T3 (OSRAM)
HR (1) HRP20170973T1 (OSRAM)
HU (1) HUE034847T2 (OSRAM)
IL (1) IL219801A (OSRAM)
IN (1) IN2012DN05175A (OSRAM)
LT (1) LT2510012T (OSRAM)
MX (1) MX2012006593A (OSRAM)
NZ (1) NZ600470A (OSRAM)
PL (1) PL2510012T3 (OSRAM)
PT (1) PT2510012T (OSRAM)
RS (1) RS56161B1 (OSRAM)
RU (1) RU2577977C2 (OSRAM)
SI (1) SI2510012T1 (OSRAM)
TW (1) TWI488642B (OSRAM)
WO (1) WO2011070088A1 (OSRAM)
ZA (1) ZA201203498B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5881604B2 (ja) * 2010-06-15 2016-03-09 国立大学法人大阪大学 癌予後判定可能な抗体、および癌予後判定方法
CA2833477A1 (en) 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use
JP2014117191A (ja) * 2012-12-13 2014-06-30 Fisheries Research Agency リン酸化中性スフィンゴミエリナーゼ１、抗リン酸化中性スフィンゴミエリナーゼ１抗体、中性スフィンゴミエリナーゼ１変異体、及びそれらの用途
US10428159B2 (en) 2014-09-09 2019-10-01 Board Of Regents, The University Of Texas System Blocking monoclonal antibodies to AGR2 and its receptor C4.4A
AU2016249839B2 (en) 2015-04-17 2021-09-09 Ventana Medical Systems, Inc. Antibodies, compositions, and immunohistochemistry methods for detecting C4.4a
RU2018123709A (ru) * 2015-12-04 2020-01-09 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Новые антитела для лечения онкологических заболеваний
WO2017156280A1 (en) * 2016-03-09 2017-09-14 Viba Therapeutics, Inc. Methods of treating cancer using monoclonal antibodies to agr2 and c4.4a
CA3049661A1 (en) 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules
CN110234662A (zh) 2017-01-26 2019-09-13 瑟罗泽恩公司 组织特异性wnt信号增强分子和其用途
JP7052389B2 (ja) * 2018-02-07 2022-04-12 株式会社三洋物産 遊技機
EP3820499A4 (en) 2018-07-09 2022-07-13 Surrozen Operating, Inc. TISSUE SPECIFIC WNT SIGNAL ENHANCEMENT MOLECULES AND USES
WO2020018973A1 (en) * 2018-07-20 2020-01-23 Duke University Anti-lypd3 car t-cell therapy for the treatment of cancer
EP3878966A4 (en) * 2018-11-08 2022-10-26 National University Corporation Kagawa University PROCESS FOR THE PRODUCTION OF A RARE SUGAR COMPOUND AND RARE SUGAR COMPOSITION
CN111349164B (zh) * 2018-12-21 2023-05-26 艾比玛特医药科技（上海）有限公司 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
AU2020298326A1 (en) 2019-06-21 2022-01-27 Children's National Medical Center Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context
US20220395532A1 (en) 2019-11-08 2022-12-15 Humanigen, Inc. Epha3 directed car-t cells for treatment of tumors
TW202233656A (zh) 2020-11-16 2022-09-01 美商蘇羅森營運公司 肝特異性wnt訊號增強分子及其用途
IL315431A (en) 2022-03-16 2024-11-01 Pentixapharm Ag Antibodies against lypd3
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
EP0938505B1 (en) * 1996-05-31 2002-03-06 Health Research, Inc. Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1220919A2 (en) * 1999-09-29 2002-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Metastasis-associated antigen c4.4a
AU2002314495A1 (en) * 2001-06-20 2003-01-02 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
BRPI0510883B8 (pt) * 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
US8105602B2 (en) * 2006-12-08 2012-01-31 Tactic Pharma, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
CA2833477A1 (en) * 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use

Also Published As

Publication number Publication date
JP5989544B2 (ja) 2016-09-07
US20120321619A1 (en) 2012-12-20
ES2632748T3 (es) 2017-09-15
EP3144323A3 (en) 2017-05-31
HUE034847T2 (en) 2018-03-28
IN2012DN05175A (OSRAM) 2015-10-23
AU2010329904B2 (en) 2015-07-09
JP2018019721A (ja) 2018-02-08
TWI488642B (zh) 2015-06-21
BR112012013915A8 (pt) 2017-12-26
US20170158775A1 (en) 2017-06-08
SI2510012T1 (sl) 2017-08-31
WO2011070088A1 (en) 2011-06-16
PT2510012T (pt) 2017-07-13
RU2577977C2 (ru) 2016-03-20
EP2510012A1 (en) 2012-10-17
NZ600470A (en) 2015-02-27
CN102812047A (zh) 2012-12-05
CY1119051T1 (el) 2018-01-10
TW201134485A (en) 2011-10-16
DK2510012T3 (en) 2017-07-31
JP6240696B2 (ja) 2017-11-29
LT2510012T (lt) 2017-07-25
KR101931820B1 (ko) 2018-12-21
ZA201203498B (en) 2015-10-28
IL219801A (en) 2016-08-31
HRP20170973T1 (hr) 2017-09-22
CA2783338A1 (en) 2011-06-16
HK1178920A1 (en) 2013-09-19
RS56161B1 (sr) 2017-11-30
KR20120116958A (ko) 2012-10-23
RU2012128343A (ru) 2014-01-20
JP2016104820A (ja) 2016-06-09
PL2510012T3 (pl) 2017-09-29
EP2510012B1 (en) 2017-04-19
CN102812047B (zh) 2015-08-26
BR112012013915A2 (pt) 2017-01-10
IL219801A0 (en) 2012-07-31
MX2012006593A (es) 2012-06-28
EP3144323A2 (en) 2017-03-22
JP2013513369A (ja) 2013-04-22
AU2010329904A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
AR079340A1 (es) Anticuerpos anti-c4.4a y usos de los mismos
CU23833A3 (es) Anticuerpos antimesotelina
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CL2019002717A1 (es) Receptores de unión a antígeno mejorados.
PE20180798A1 (es) Constructos de anticuerpos biespeficos que se unen a mesotelina y cd3
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
PE20180607A1 (es) Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos
EA202092735A1 (ru) Антагонизирующее cd73 антитело
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
CL2009000567A1 (es) Anticuerpo monoclonal que enlaza especificamente tyrp1 humano; fragmento de cualquiera de los anticuerpos antes indicado; acido nucleico que codifica en anticuerpo o fragmento; vector de expresion; celula recombinante; uso del anticuerpo o fragmento para tratar cancer.
PE20200757A1 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
AR093557A1 (es) Anticuerpos anti-ceacam5 y usos de estos
MX2019011656A (es) Formatos mejorados de receptor de union a antigeno.
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
CL2008003527A1 (es) Conjugado de anticuerpo o porcion de union de antigeno del mismo, que se une a la proteina tirosina quinasa 7 (ptk-7/cck4); composicion que lo comprende; acido nulceico cidificante del anticuerpo; vector y celula huesped; uso del conjugado para tratar o prevenir una enfermedad de celulas tumorales que expresan ptk7
CL2013002203A1 (es) Molecula de union a antigeno (abm) que se une al antigeno carcinoembrionario humano (cea) unido a membrana; anticuerpo que se une a cea unido a membrana; polinucleotido que los codifica; vector; celula huesped; composicion que comprende al abm o al anticuerpo; y su uso para tratar un cancer que expresa niveles anormales de cea.
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
BR112014001573B8 (pt) Molécula fv ao antígeno multivalente
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
CO6571892A2 (es) Composiciones y métodos para el diagnostico y tratamiento de tumores
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
BR112021009275A2 (pt) Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira.
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)

Legal Events

Date Code Title Description
FB Suspension of granting procedure